Robinhood Markets, Inc. vs Johnson & Johnson — how do they compare? Robinhood Markets, Inc. trades at $107.43 (market cap $89.13B), while Johnson & Johnson trades at $249.38 (market cap $598.96B). The key difference: Johnson & Johnson is far larger — about 6.7× Robinhood Markets, Inc.'s market cap, and Johnson & Johnson pays a 2.15% dividend while Robinhood Markets, Inc. pays none. Which is the better fit depends on your goals.
| HOOD | JNJ | |
|---|---|---|
Market Cap | $89.13B | $598.96B |
Sector | Technology | Health |
52-Week High | $152.46 | $267.24 |
52-Week Low | $65.16 | $164.36 |
Enterprise Value | $90.33B | $631.90B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.15% |
Signals from Pluang's Aura AI — not financial advice
Robinhood Markets (HOOD) trades at $99.41, down 0.55% on the day, with technical indicators showing a bearish short-term trend. The stock has strong fundamentals, including 2025 revenue of $4.47 billion and net income of $1.88 billion, with a net margin of 42.09%. Recent news highlights institutional selling and CFO share disposals, but analyst consensus remains bullish with a $113.21 price target. Cash flow improved significantly in 2025 to $1.20 billion net.
The outlook for HOOD is mixed: strong profitability and growth support upside potential, but near-term technical weakness and insider selling pose risks. Investors should weigh robust financials against market sentiment and competitive pressures in the fintech sector.
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Trailing returns across standard periods
Latest headlines on both assets
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →